The Biomedical Advanced Research and Development Authority (BARDA), through its BioMaP Consortium, has outlined a proposed development effort to turn stored manufacturing equipment into a platform for emergency drug delivery. The Repurposing Equipment for Drug Delivery (REDD) draft Statement of Objectives (SOO) calls for a recipient to relocate, restore, and repurpose specialized equipment originally designed to manufacture a glass-free, collapsible primary drug container. Chemical medical countermeasures are the primary focus, with a preference for platforms applicable across multiple chemical, biological, radiological, and nuclear (CBRN) indications.
EverGlade previously covered BARDA’s REDD Request for Information, which explored industry capabilities for repurposing the equipment. The draft SOO now provides a more detailed technical scope, including equipment transfer, container and process optimization, verification activities, and potential device-development options. While the earlier RFI was issued through the Rapid Response Partnership Vehicle (RRPV), the draft SOO identifies the BioMaP-Consortium OT vehicle.
Key Details
| Detail | Information |
|---|---|
| Project | Repurposing Equipment for Drug Delivery (REDD) |
| Current document | Draft Statement of Objectives |
| Vehicle identified | BioMaP-Consortium OT vehicle, Domain 2 |
| Proposed period of performance | No more than 18 months from award |
| Equipment transfer deadline | No later than April 1, 2027 |
| Proposal deadline | Not specified in the draft SOO |
What BARDA Wants to Repurpose
BARDA’s Chemical Medical Countermeasures Program holds equipment customized under a prior contract for an emergency autoinjector platform. That contract ended prematurely, and the equipment is now stored at a BARDA facility in Perry Point, Maryland. The underlying technology uses a collapsible primary drug container (PDC) made from high-barrier films rather than glass.
The equipment supports discrete manufacturing steps, including film handling and cleaning, container forming, pre-assembly, and fill/finish sealing. The draft also describes associated filling, leak-detection, seal-testing, assembly, and inspection equipment. BARDA identifies an authoritative equipment list and a Device Readiness Transfer Package as resources to inform technical planning, setup, and requalification.
The objective is not simply to restart the previous production line. BARDA wants to maximize the value of its prior investment by repurposing these assets for a drug closure system and delivery device, such as an autoinjector or another single-use delivery system. Platforms with broader emergency-use applications across BARDA’s portfolio are encouraged.
Proposed Technical Scope
The draft describes a progression from equipment recovery to a verified container-manufacturing process:
Equipment transfer and restoration. Develop and execute a logistics plan to move the equipment and consumables from Perry Point to the recipient’s facility by April 1, 2027. Assess serviceability, set up the equipment, and bring it into operational condition.
Container and process optimization. Determine suitable PVC film characteristics and optimize cleaning, forming, filling, and sealing. A simple, single-chamber PDC prototype is preferred at this stage. The work must address leachables, seal integrity, shelf life, and sterilization.
Process verification. Conduct media or water runs sufficient to confirm container characteristics and container closure integrity, documenting the optimization and verification results.
Platform and regulatory planning. Identify delivery platforms that could use the optimized container and develop corresponding regulatory plans.
The draft also identifies two options: designing a delivery device around the PDC, followed by qualification, engineering runs, and generation of data needed for FDA approval of an autoinjector. The latter option includes identifying potential medical countermeasure products for use with the device.
Who Should Evaluate This Opportunity?
Based on the proposed scope, REDD is most relevant to teams that can combine drug-delivery device development with manufacturing equipment integration, container-materials expertise, fill/finish process development, sterilization, and regulatory planning. A device concept alone would not address the draft’s requirements to receive, restore, and operate the existing equipment.
Equipment condition is a central execution risk. The draft specifically requires planning for assets that may arrive damaged, degraded, or nonfunctional, along with contingencies for setup and requalification within the proposed 18-month schedule. Sterilization is another critical issue, particularly the interaction between PVC characteristics and byproducts associated with radiation-based methods.
Property and Intellectual Property Considerations
Taking possession of the equipment does not mean acquiring ownership. The draft states that title to the government-furnished equipment will remain with the government, with the recipient responsible for safeguarding, maintaining, and accounting for it.
Teams should also distinguish background intellectual property associated with the existing equipment and PDC design from new IP developed through REDD. The government requires at least Government Purpose Rights to IP developed with government funds, subject to the BioMaP-Consortium Base Agreement. BARDA indicates that subject matter experts will be available to support IP considerations.
What Prospective Teams Should Do Now
The draft provides a basis for evaluating technical fit before final solicitation requirements are confirmed. Prospective teams should assess whether their facilities can accommodate the equipment, identify gaps in materials or manufacturing expertise, and build a realistic restoration and development schedule. Early diligence should also address background IP access and the path from an optimized container to a viable delivery platform.
EverGlade is a national advisory firm helping innovators navigate the federal funding ecosystem. We support companies across the funding lifecycle, from early-stage strategy through proposal development, negotiations, and post-award execution, ensuring you win the award and deliver the program.
For additional information on where your capabilities could plug into this upcoming program, schedule a conversation with our team.
